Your session is about to expire
← Back to Search
PV-10 (10% rose bengal disodium) for Liver Cancer
Study Summary
This trial will test a new cancer drug, PV-10, given as a single injection. It will measure safety, how well the body tolerates it, and how it affects tumor growth in people with liver cancer that cannot be removed by surgery.
- Liver Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Uveal Melanoma
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Melanoma
- Ocular Melanoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 2 trial • 80 Patients • NCT00521053Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What other investigations involving PV-10 (10% rose bengal disodium) have been conducted?
"Currently, 3 clinical trials are underway which involve PV-10 (10% rose bengal disodium), 1 of which is in the last phase. Most of these projects are located around Tampa, Florida; however there are 15 other sites conducting research with this drug."
How many participants are the maximum capacity of this research endeavor?
"This clinical trial is no longer in the process of enrolling participants, having first been posted on October 1st 2009. However, individuals with pancreatic metastatic cancer still have 3,616 active studies they can explore while those interested in PV-10 (10% rose bengal disodium) can look into three existing trials still accepting recruits."
Are there any vacancies for participants in this clinical investigation?
"Regrettably, this trial has concluded its recruitment period. It was posted on October 1st 2009 and last amended on the 31st of October in 2022. However, for those searching for other studies currently enrolling patients with pancreatic metastatic cancer, there are 3616 trials available; likewise, 3 clinical studies related to 10% rose bengal disodium (PV-10) remain active at present."
Has this experimental research ever been attempted before?
"Currently, there are 3 ongoing clinical trials for PV-10 (10% rose bengal disodium) scattered throughout 13 cities and 3 countries. Provectus Biopharmaceuticals, Inc., pioneered the first Phase 1 study of this drug in 2009 with 78 participants; since then 5 more studies have been conducted."
Does PV-10 (10% rose bengal disodium) present any significant risk to patients?
"PV-10 (10% rose bengal disodium) has only undergone preliminary testing, so it scored a 1 on our team's safety assessment scale."
Share this study with friends
Copy Link
Messenger